化合物RO 5-3335
化合物RO 5-3335 用途与合成方法
RUNX1-CBFβ interaction
Ro5-3335 has antiproliferative activity against human CBF leukemia cell lines, with IC
50
s of 1.1 μM, 21.7 μM and 17.3 μM for ME-1, Kasumi-1 and REH, respectively.
Ro5-3335 inhibits definitive hematopoiesis in zebrafish embryos.
Ro5-3335 does not completely break apart RUNX1-CBFβ interaction, but changes the conformation of their complex or increases the distance between RUNX1 and CBFβ in the complex.
Ro5-3335 is identified as an inhibitor of RUNX1–CBFβ function in zebrafish models.
Ro5-3335 rescues preleukemic phenotype in a RUNX1-ETO transgenic zebrafish.
Ro5-3335 (300 mg/kg/d; p.o; for 30 days) reduces leukemia burden in a mouse CBFB-MYH11 leukemia model.
| Animal Model: | C57BL/6 mice (leukemic model) |
| Dosage: | 300 mg/kg |
| Administration: | Oral administration; daily; for 30 days |
| Result: | Reduced the number of c-kit + cells in the transplanted mice and leukemic cell infiltration in the livers, bone marrow and spleen. |
化合物RO 5-3335 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-108470 | 1 mg | 545 | ||
| 2024-04-30 | R0223 | Ro 5-3335 | 30195-30-3 | 10mg | 550 |
